Skip to main content

PepGen Inc.

corporate_fare Company Profile

PepGen Inc.

PEPG·NASDAQ·Life Sciences·CIK 0001835597

PepGen Inc. is a clinical-stage biotechnology company focused on developing advanced oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides (CPPs) to improve how conjugated oligonucleotide therapeutics are absorbed and become active. These EDO peptides are designed to optimize tissue penetration, cellular uptake, and delivery to the cell nucleus. Preclinical studies have shown they can transport oligonucleotides into various target tissues, including smooth, skeletal, and cardiac muscle. Clinical trials have demonstrated strong delivery and activity of oligonucleotides in skeletal muscle. PepGen is currently addressing myotonic dystrophy type 1 (DM1), a multi-systemic neuromuscular disease with no approved therapies. The company is developing PGN-EDODM1 for DM1. PGN-EDODM1's therapeutic oligonucleotide component is engineered to bind to the pathogenic cytosine-uracil-guanine (CUG) repeat expansion in the myotonic dystrophy protein kinase (DMPK) messenger RNA (mRNA) of DM1 patients. By binding to these expanded repeats, PGN-EDODM1 reduces their ability to sequester RNA binding proteins like MBNL1, a key RNA splicing factor. This liberation of MBNL1 corrects downstream mis-splicing events that cause DM1 pathology. The company anticipates expanding the EDO technology to other severe diseases with significant unmet needs.

PepGen Inc. (NASDAQ:PEPG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for PEPG at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • PepGen Faces Clinical Hold on Lead DM1 Program, Discontinues DMD Program, and Reports Dilutive $107.6M Offering

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$89.66M
Diluted EPS
-$2.12
Op. Cash Flow
-$81.64M
Free Cash Flow
-$81.9M
Operating Income
-$93.61M
Cash & Equivalents
$60.51M
Debt / Equity
0.00×
Shares Outstanding
68.87M sh
Source: 10-K · filed 2026-03-04 · accession 0001193125-26-091536
$3.79 +0.26% today
52-week range · as of 2026-11-17 $1.31 – $7.8
Market cap
$261.81M
Volume
4.4M (0.7× avg)
3-mo avg 6.1M
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PEPG - Filings & News (Page 2)

PEPG
Mar 04, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $3.79 info
Change: -$1.71 (-31%) info
Market Cap: $261.808M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets